

MALDI-IHC-Guided In-Depth Spatial Proteomics Targeted and Untargeted MSI Combined

B.S.R. Claes¹, K. K. Krestensen¹, G. Yagnik², A Grgic¹, C. Kuik¹, M.J. Lim², K.J. Rothschild², M. Vandenbosch¹, R.M.A. Heeren¹ ¹Maastricht MultiModal Molecular Imaging (M4I) Institute, Division of Imaging Mass Spectrometry, Maastricht, Netherlands ²AmberGen, Inc., Billerica, Massachusetts, 01821, United States

Introduction

Recently, MALDI-IHC was published as novel technology, utilizing the strengths of matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) and immunohistochemistry (IHC), achieving highly multiplexed, targeted imaging of biomolecules in tissue. This new technique, enabled workflows to target molecules of interest using MALDI-MSI which is usually reserved for standard IHC. In this poster, the utility of targeted MALDI-IHC and its complementarity with untargeted on-tissue bottom-up spatial proteomics is explored using breast cancer tissue. Furthermore, the MALDI-2 effect on MALDI-IHC treated tissue was investigated.

Method



Conclusions

Numerous peptides could be tentatively assigned to proteins, based on untargeted on-tissue digestion and image guided LC-MS of which three proteins were also part of the antibody panel (vimentin, keratins, and actin). Post-ionization with MALDI-2 showed an increased intensity of the PC-MTs and suggests options for the development of new mass-tags. Although the on-tissue digestion covered a wider range of proteins, the MALDI-IHC allowed for easy and straightforward detected in untargeted approaches. The combination of the multiplexed MALDI-IHC with image-guided proteomics showed great potential to further investigate diseases by providing complementary information from the same tissue section and without the need for customized instrumentation.

Acknowledgements

This work was supported by the Dutch province of Limburg through the LINK program. Portions of this work were funded by the SBIR grant CA236097 from the NIH (National Cancer Institute) to AmberGen, Inc. R.M.A.H., the M4i team and AmberGen, Inc. acknowledges the continuous technical support of Bruker Daltonics during this project. B.S.R.C. and R.M.A.H. acknowledge financial support from the NIH of the United States of America-i.e., R01 CA213492.



Maastricht MultiModal Molecular Imaging (M4i) Institute Imaging Mass Spectrometry, Maastricht University Universiteitssingel 50, 6229 ER Maastricht The Netherlands